Kare Schultz - 08 Feb 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: President and CEO, Director
Signature: /s/ Dov Bergwerk as attorney-in-fact for Kare Schultz
Issuer symbol: TEVA
Transactions as of: 08 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 10 Feb 2022, 15:12:22 UTC
Previous filing: 03 Nov 2021
Next filing: 02 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+26,867	+2.6%		1,067,449	09 Feb 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-26,867	-100%	$0.000000^*	0	09 Feb 2022	Ordinary Shares	26,867		Direct	F2, F3
transaction	TEVA	Restricted Share Units	Award	$0	+162,593		$0.000000	162,593	08 Feb 2022	Ordinary Shares	162,593		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on February 9, 2018, with 26,867 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.
F4	Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.